Autologous mesenchymal stem cells in chronic stroke.
Autologous mesenchymal stem cells in chronic stroke.
复制标题
慢性中风中的自体间充质干细胞。
DOI：
10.1159/000333381
复制
发表时间：
2011-01
影响因子：
1.9
通讯作者：
Airan B
中科院分区：
文献类型：
--
作者：
Bhasin A;Srivastava MV;Kumaran SS;Mohanty S;Bhatia R;Bose S;Gaikwad S;Garg A;Airan B
细胞移植在目前的情况下是一种“炒作和希望”。它正处于发展的早期阶段，有望恢复慢性疾病的功能。间充质干细胞（MSC）移植在中风患者中显示出显着的改善，减少临床和功能缺陷。它们是可行的和多能的，并具有寻的特性。本研究采用临床评分和功能成像（血氧水平依赖性和弥散张量成像技术）评估慢性卒中患者自体MSC移植的安全性、可行性和有效性。招募了12名慢性卒中患者;入选标准为卒中持续3个月至1年，手部肌肉运动强度至少为2，NIHSS评分为4-15，患者必须有意识并能够理解。在基线、8周和24周后评估Fugl Meyer（FM）、改良Barthel指数（mBI）、MRC、Ashworth音调分级量表评分和功能成像扫描。在无菌条件下抽吸骨髓，用无动物血清培养基（Stem Pro SFM）扩增MSC 3周。6名患者平均静脉注射50-60 × 106个细胞，随后进行8周的物理治疗。6例患者作为对照。这是一项非随机实验对照试验。干细胞组患者的临床和放射学扫描正常。无死亡或细胞相关不良反应。MSC组第1、3、5、7天的实验室检查也正常，直至末次随访。与对照组相比，干细胞组的FM和mBI显示出适度增加。与对照组相比，干细胞输注后Brodmann区BA 4和BA 6的簇活化数量增加，表明神经可塑性。旨在恢复脑卒中功能的MSC治疗是安全可行的。需要进一步的随机对照试验来评价其疗效。
Cell transplantation is a ‘hype and hope’ in the current scenario. It is in the early stage of development with promises to restore function in chronic diseases. Mesenchymal stem cell (MSC) transplantation in stroke patients has shown significant improvement by reducing clinical and functional deficits. They are feasible and multipotent and have homing characteristics. This study evaluates the safety, feasibility and efficacy of autologous MSC transplantation in patients with chronic stroke using clinical scores and functional imaging (blood oxygen level-dependent and diffusion tensor imaging techniques). Twelve chronic stroke patients were recruited; inclusion criteria were stroke lasting 3 months to 1 year, motor strength of hand muscles of at least 2, and NIHSS of 4–15, and patients had to be conscious and able to comprehend. Fugl Meyer (FM), modified Barthel index (mBI), MRC, Ashworth tone grade scale scores and functional imaging scans were assessed at baseline, and after 8 and 24 weeks. Bone marrow was aspirated under aseptic conditions and expansion of MSC took 3 weeks with animal serum-free media (Stem Pro SFM). Six patients were administered a mean of 50–60 × 106 cells i.v. followed by 8 weeks of physiotherapy. Six patients served as controls. This was a non-randomized experimental controlled trial. Clinical and radiological scanning was normal for the stem cell group patients. There was no mortality or cell-related adverse reaction. The laboratory tests on days 1, 3, 5 and 7 were also normal in the MSC group till the last follow-up. The FM and mBI showed a modest increase in the stem cell group compared to controls. There was an increased number of cluster activation of Brodmann areas BA 4 and BA 6 after stem cell infusion compared to controls, indicating neural plasticity. MSC therapy aiming to restore function in stroke is safe and feasible. Further randomized controlled trials are needed to evaluate its efficacy.
登录
查看更多内容
影响因子：
7.5
作者：
Chase LG;Lakshmipathy U;Solchaga LA;Rao MS;Vemuri MC
通讯作者：
Vemuri MC
影响因子：
8.3
作者：
Komitova, M;Mattsson, B;Eriksson, PS
通讯作者：
Eriksson, PS
影响因子：
11.2
作者：
Bang, OY;Lee, JS;Lee, G
通讯作者：
Lee, G
影响因子：
5.7
作者：
Jiang, Quan;Zhang, Zheng Gang;Chopp, Michael
通讯作者：
Chopp, Michael
DOI：
10.1073/pnas.182296499
发表时间：
2002-09-03
影响因子：
11.1
作者：
Jin, KL;Zhu, YH;Greenberg, DA
通讯作者：
Greenberg, DA